A cheap, widely available antibiotic may soon change how doctors treat one of the most dangerous forms of tuberculosis. A new study from the National University of Singapore has found that doxycycline, a common antibiotic, could significantly improve survival rates in patients with Central Nervous System Tuberculosis (CNS-TB) — a rare but often fatal TB infection that attacks the brain and spinal cord.
The findings, published in the Journal of Neuroinflammation, offer renewed hope for families and clinicians struggling with one of TB’s most devastating complications.
What Makes CNS-TB So Deadly?
Although tuberculosis is largely known for infecting the lungs, CNS-TB affects only 1–2% of all TB patients. Yet it has a disproportionately high fatality rate. Many survivors are left with long-term neurological damage because the infection triggers intense brain inflammation and disrupts blood vessels, making it difficult for TB medicines to reach affected brain tissue.
Children and people with weakened immune systems are most vulnerable.
With 10.8 million TB cases globally in 2023 and around 1,100 new active cases reported annually in Singapore, experts have long stressed the urgent need for better treatment strategies for the more severe forms of TB.
Why doxycycline? A Familiar Drug With New Potential
Researchers at the Yong Loo Lin School of Medicine discovered that doxycycline, when paired with standard TB drugs, produces multiple benefits:
- Reduces brain inflammation
- Improves blood vessel integrity, helping TB medicines penetrate brain tissue
- Boosts survival rates in preclinical models
- Blocks two major drivers of brain damage —
matrix metalloproteinases (MMPs) and neutrophil extracellular traps (NETs), both found at high levels in the cerebrospinal fluid of affected patients
The study reviewed samples from 72 children with tuberculous meningitis and found abnormally elevated MMPs and NETs, confirming their role in disease progression.
To simulate real disease conditions, the team built an advanced laboratory model that closely mimicked human CNS-TB. The results were striking: doxycycline combined with standard therapy led to dramatically higher survival and reduced inflammation.
Researchers stated that doxycycline is “inexpensive, safe, and ready to use.”
Associate Professor Catherine Ong Wei Min, who led the study, emphasised the real-world advantages of using repurposed drugs.
“Doxycycline is inexpensive, safe, and widely available. If our Phase II trials confirm these results, this treatment could be rolled out rapidly through national TB programmes without the usual delays in new drug development.”
This approach—using existing drugs for new conditions—could also speed up treatments for other inflammatory brain diseases.
Phase II Trial Underway Across Southeast Asia
The ongoing Phase II clinical trial, funded by the National Medical Research Council of Singapore, is currently taking place across Singapore, Malaysia, and Indonesia. If the results are positive, clinicians may soon gain a practical, scalable treatment option for CNS-TB.
As Professor Ong noted:
“Our goal is to give patients a better chance at survival and recovery using drugs that already exist — because innovation doesn’t always mean invention.”
Why This Matters for Public Health
- CNS-TB is rare but extremely lethal.
- Current treatment options are limited and often ineffective due to poor drug penetration into the brain.
- A low-cost, repurposed antibiotic could transform care in low- and middle-income countries, where the TB burden is highest.
- Faster rollout is possible because doxycycline is already approved globally.
The study reinforces a growing scientific movement: repurposing affordable drugs to save lives, especially in infections that disproportionately affect vulnerable populations.
Frequently Asked Questions (FAQ)
1. What is Central Nervous System Tuberculosis?
CNS-TB is a severe form of TB that infects the brain and spinal cord, causing inflammation, neurological damage, and high mortality.
2. Is doxycycline currently used to treat TB?
Doxycycline is not part of the standard TB regimen, but emerging evidence suggests it may enhance treatment effectiveness in CNS-TB.
3. How soon could this treatment become available?
If Phase II trials confirm the findings, the therapy could be introduced briefly because doxycycline is already approved, affordable, and widely accessible.
4. Who is most at risk of CNS-TB?
Children, people with weakened immune systems, and untreated TB patients are at higher risk.